Hypoxia‐inducible factor‐1α can reverse the Adriamycin resistance of breast cancer adjuvant chemotherapy by upregulating transferrin receptor and activating ferroptosis
The FASEB Journal · 2024
DOI: 10.1096/fj.202401119r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Xiaojie Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, P.R. China. Hauptthemen laut MEDLINE: Breast Neoplasms, Doxorubicin, Drug Resistance, Neoplasm, Ferroptosis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, National Key Research and Development Project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Breast cancer is a common malignant tumor in women. Ferroptosis, a programmed cell death pathway, is closely associated with breast cancer and its resistance. The transferrin receptor (TFRC) is a key factor in ferroptosis, playing a crucial role in intracellular iron accumulation and the occurrence of ferroptosis. This study investigates the influence and significance of TFRC and its upstream transcription factor hypoxia‐inducible factor‐1α (HIF1α) on the efficacy of neoadjuvant therapy in breast cancer. The differential gene obtained from clinical samples through genetic sequencing is TFRC. Bioinformatics analysis revealed that TFRC expression in breast cancer was significantly greater in breast cancer tissues than in normal tissues, but significantly downregulated in Adriamycin (ADR)‐resistant tissues. Iron‐responsive element‐binding protein 2 (IREB2) interacts with TFRC and participates in ferroptosis. HIF1α, an upstream transcription factor, positively regulates TFRC. Experimental results indicated higher levels of ferroptosis markers in breast cancer tissue than in normal tissue. In the TAC neoadjuvant regimen‐sensitive group, iron ion (Fe 2+ ) and malondialdehyde (MDA) levels were greater than those in the resistant group (all p < .05). Expression levels of TFRC, IREB2, FTH1, and HIF1α were higher in breast cancer tissue compared to normal tissue. Additionally, the expression of the TFRC protein in the TAC neoadjuvant regimen‐sensitive group was significantly higher than that in the resistant group (all p < .05), while the difference in the level of expression of IREB2 and FTH1 between the sensitive and resistant groups was not significant ( p > .05). The dual‐luciferase assay revealed that HIF1α acts as an upstream transcription factor of TFRC ( p < .05). Overexpression of HIF1α in ADR‐resistant breast cancer cells increased TFRC, Fe 2+ , and MDA content. After ADR treatment, the cell survival rate decreased significantly, and ferroptosis could be reversed by the combined application of Fer‐1 (all p < .05). In conclusion, ferroptosis and chemotherapy resistance are correlated in breast cancer. TFRC is a key regulatory factor influenced by HIF1α and is associated with chemotherapy resistance. Upregulating HIF1α in resistant cells may reverse resistance by activating ferroptosis through TFRC overexpression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, P.R. China.
- Department of Breast Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, P.R. China.
ORCID-Profile: Xiaojie Yu, Qingqun Guo, Haojie Zhang, Xiaohong Wang, Yong Han, Zhenlin Yang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- National Key Research and Development Project
Zitieren
APA
Yu, X., Guo, Q., Zhang, H., Wang, X., Han, Y., & Yang, Z. (2024). Hypoxia‐inducible factor‐1α can reverse the Adriamycin resistance of breast cancer adjuvant chemotherapy by upregulating transferrin receptor and activating ferroptosis. The FASEB Journal. https://doi.org/10.1096/fj.202401119r
Vancouver
Yu X, Guo Q, Zhang H, Wang X, Han Y, Yang Z. Hypoxia‐inducible factor‐1α can reverse the Adriamycin resistance of breast cancer adjuvant chemotherapy by upregulating transferrin receptor and activating ferroptosis. The FASEB Journal. 2024. doi:10.1096/fj.202401119r
BibTeX
@article{Yu2024,
author = {Yu, Xiaojie and Guo, Qingqun and Zhang, Haojie and Wang, Xiaohong and Han, Yong and Yang, Zhenlin},
title = {Hypoxia‐inducible factor‐1α can reverse the Adriamycin resistance of breast cancer adjuvant chemotherapy by upregulating transferrin receptor and activating ferroptosis},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202401119r}
}
EUVIMED